Related Experiment Video
Updated: Mar 27, 2026
09:31
In Vivo, Percutaneous, Needle Based, Optical Coherence Tomography of Renal Masses
Published on: March 30, 2015
9.4K
Hematologic Parameters to Predict Small Renal Mass Biopsy Pathology.
Madhur Nayan1, Patrick O Richard1, Michael A S Jewett1
1Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada.
Clinical Genitourinary Cancer
|January 19, 2016
Summary
The platelet-to-lymphocyte ratio (PLR) did not significantly differ between benign and primary renal malignancies. However, a higher PLR may help identify nonrenal malignancies in small renal mass evaluations.
Area of Science:
- Oncology
- Hematology
- Pathology
Background:
- Elevated neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios (PLRs) are linked to various cancers.
- This study investigates hematologic parameters and their relation to renal tumor biopsy findings.
Purpose of the Study:
- To evaluate associations between hematologic parameters and renal tumor biopsy pathology.
- To determine if hematologic markers can differentiate benign, primary renal, and nonrenal malignancies.
Main Methods:
- Retrospective review of 475 small renal mass biopsy specimens (2001-2013).
- Analysis of complete blood counts and biopsy pathology (benign, primary renal malignancy, nonrenal malignancy).
- Statistical comparison of hematologic parameters and logistic regression modeling.
Main Results:
- The platelet-to-lymphocyte ratio (PLR) differed significantly among the three pathology groups.
- PLR was significantly higher in nonrenal malignancies compared to primary renal malignancies (P=.013).
- A PLR cutoff of 202.9 demonstrated 63.6% sensitivity and 82.2% specificity for detecting nonrenal malignancy.
Conclusions:
- Hematologic parameters showed no significant difference between benign and primary renal malignant masses.
- The PLR may serve as a cost-effective marker to aid in distinguishing nonrenal malignancies during small renal mass workup.
